doxorubicin + medroxyprogesterone acetate

Doxorubicin + medroxyprogesterone acetate is a combination regimen of two pharmaceutical agents used in oncology, primarily studied for the treatment of advanced, hormone-resistant breast cancer. Doxorubicin is an anthracycline antibiotic that acts as a cytotoxic chemotherapy agent by intercalating DNA and inhibiting topoisomerase II, leading to DNA damage and apoptosis in rapidly dividing cells. Medroxyprogesterone acetate is a synthetic progestin (hormonal therapy) that exerts antitumor effects through modulation of hormone receptors and inhibition of tumor cell proliferation. The combination has been investigated for potential synergistic effects in patients whose cancers are resistant to standard hormonal therapies[1][3]. Clinical studies have shown increased response rates with the addition of high-dose medroxyprogesterone acetate to weekly doxorubicin compared to doxorubicin alone, though with notable toxicity such as weight gain and fluid retention[1].